- Home
- XAIR vs PPBT Comparison
XAIR vs PPBT Comparison
Compare XAIR & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XAIR | PPBT |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 4.4M |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | XAIR | PPBT |
|---|---|---|
| Price | $0.49 | $3.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 260.5K | 5.3K |
| Earning Date | 06-16-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,705,000.00 | N/A |
| Revenue This Year | $122.00 | N/A |
| Revenue Next Year | $58.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 219.67 | N/A |
| 52 Week Low | $0.15 | $0.41 |
| 52 Week High | $3.78 | $5.18 |
Technical Indicators
Market Signals| Indicator | XAIR | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 43.38 |
| Support Level | $0.44 | $3.70 |
| Resistance Level | $0.60 | $4.39 |
| Average True Range (ATR) | 0.05 | 0.28 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 41.80 | 29.29 |
Price Performance
Historical ComparisonAbout XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.